| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
The central nervous system (CNS) is a key site of extramedullary disease in acute lymphoblastic leukemia (ALL). In this study, we investigated the detailed phenotypic, genetic, and transcriptional biology of leukemic cells reside in the CNS. With primary human B-ALL cells and xenograft recipients of primary samples, we demonstrate that leukemic cells that have infiltrated the CNS show features of adaptation to hypoxia and molecular targeted therapy specifically reduces the burden of CNS disease in a xenograft model. Furthermore, we demonstrated a possible novel therapeutic approach against CNS leukemia with CART cells.
|
